Oral L-NAME supplementation accelerates the progression of kidney disease in diabetic mice
Taken together, our results demonstrate that L-NAME accelerates the progression of DKD in C57BLKS/J Lep<sup>db</sup> mice, with detectable signs of kidney dysfunction after 3 weeks of treatment. Therefore, this model could be used to assess the therapeutic potential of novel interventions against DKD.
Authors
- Maria Novella Nicese
- Bernard M. van den Berg (ORCID: https://orcid.org/0000-0002-5726-5777)
- Roel Bijkerk (ORCID: https://orcid.org/0000-0002-6438-4133)
- Angela Koudijs
- Joris I. Rotmans (ORCID: https://orcid.org/0000-0001-9682-6234)
- Reshma A. Lalai
- M. Cristina Avramut (ORCID: https://orcid.org/0000-0002-2399-1746)
- Joris J. T. H. Roelofs (ORCID: https://orcid.org/0000-0001-9595-6571)
Institutions
- Leiden University Medical Center (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Biochemical and Biophysical Research Communications
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.bbrc.2025.152859
- Primary Topic
- Natural Antidiabetic Agents Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00